Skip to content

The efficacy of augmentation Donepezil to risperidon in treatment of autism spectrum disorders

Assessment the efficacy of augmentation donepezil to risperidon in treatment of autism spectrum disorders

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017041333406N1
Enrollment
66
Registered
2017-09-20
Start date
2017-07-06
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorders. Pervasive developmental disorders

Interventions

Sponsors

Vice Chancellor for Research of Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 17 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria: Of all patients with ASD, ranging in age from 6 to 17years; Parent's Consent; No obvious organic disease; The lack of other psychiatric disorders; Not taking other psychoactive medications other than risperidone; IQ higher than 50 on the basis of Weiland test. The exclusion criteria: In the absence of cooperation of parents after inclusion; the risk of any side effect or another disease that cause a problem in results.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Response to treatment. Timepoint: Previous the syudy, 6 weeks after study, 12 weeks after study. Method of measurement: CARS test.;Severity of Autism. Timepoint: Previous the syudy, 6 weeks after study, 12 weeks after study. Method of measurement: CARS test.

Secondary

MeasureTime frame
Drug's side effect. Timepoint: Previous the study, 6weeks after study, 12weeks after study. Method of measurement: Check list.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Neda Ghanei

Mashhad University of Medical Siences

ghanein931@mums.ac.irneda_ghanei@yahoo.com+98 51 3711 2721

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026